the BIOTECH WAR$ have expanded to include a new and unexpected target, “wealthy people”.
the victorious party wants to remove all undesirable citizens/unlikely supporters from the state in which they live. Acrimony against biotech companies and now wealthy citizens is where we are at.
Biotech companies are an insufficient sector to the politico’s, and a more expansive “Bad Guy Group” is now needed – i.e., wealthy people, especially if you live in NJ.
the BIOTECH WAR$ may represent a deeper battle going on between the “Socialist” political movement and our current “Capitalistic” economy.
Achieving political power supersedes common sense and support for the biotech business sector becomes non-existent as the sector is politically vilified.
Positive biotech product news seems to have little effect towards improving market valuations.
The BIOTECH WAR$ continue in 2019 and the people, mostly politicians, who put down, attack and denigrate the entire biotech sector, are currently “Wining” the BIOTECH WAR$. These people “target” the biotech sector as much as they can, as it is a sure way to appeal to the voting public, win votes and win elections.
The “Medicare for all” and the “drug pricing” messaging is working for all those who seek political gain.
Biotech, Medtech and the entire Healthcare sector are losing the battles, and the war as investors flee for less politically targeted sectors.
NJ residents see the "P/C", "Middle Class Only"/ Socialism wave coming.
I may need to stop being so publicly supportive of Biotech companies.
For now I will remain publicly supportive of all my biotech investments, but this situation may change as I continue to see the "P/C" movement/"Middle Class Only"/ Socialism movement accelerate.
OCREVUS (Ocrelizumab) Data Show Early Initiation of Treatment Reduces Disability Progression Over Five Years in Relapsing and Primary Progressive Multiple Sclerosis
Wed October 10, 2018 1:00 AM|Business Wire|About: RHHBY
EAST HANOVER, N.J., Oct. 9, 2018 /PRNewswire/
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
New Analyses from Pivotal Phase 3 Trials of Oral Ozanimod to Be Presented at ECTRIMS 2018
Wed October 10, 2018 7:30 AM|Business Wire|About: CELG
Incyte Announces Data for Pemigatinib, its Selective FGFR Inhibitor, to be Featured at the ESMO 2018 Congress
Tue October 9, 2018 7:30 AM|Business Wire|About: INCY
BeiGene Announces National Reimbursement Inclusion of VIDAZA® (Azacitidine for Injection) by the State Medical Insurance Administration in China
Wed October 10, 2018 6:00 AM|GlobeNewswire|About: BGNE
New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease
Wed October 10, 2018 6:30 AM|PR Newswire|About: LLY
Janssen Reports Switching to SYMTUZA™ Results in Maintained High Virologic Suppression and No Resistance Development up to 96-Weeks in Virologically Suppressed
SAN FRANCISCO, OCTOBER 3, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson unveils new 96-week data for SYMTUZA™ (darunavir 200 mg, cobicistat 150 mg, emtricitabine 200mg, and tenofovir alafenamide 10 mg; D/C/F/TAF), Adults with HIV-1
Merck snags national VA contract for its Remicade biosimilar thanks to discount pricing offer
by Eric Sagonowsky | Oct 8, 2018 11:12am
Merck has a biosimilars partnership with South Korea's Samsung Bioepis. (Merck)
Merck’s Renflexis hasn’t made much of a splash on the market since its FDA approval last April, but the company has now won business with the Department of Veterans Affairs thanks to a pricing offer that beat out its rivals.
Novartis Looks To Maintain Market Strength In Multiple Sclerosis Space
Single dose of J&J's Stelara shows treatment effect in late-stage UC study
Oct. 9, 2018 8:59 AM ET|By: Douglas W. House, SA News Editor
Janssen Announces Exclusive, Worldwide License Agreement with Arrowhead Pharmaceuticals to Develop and Commercialize a New Treatment for Chronic Hepatitis B Viral Infection
TITUSVILLE, N.J., October 4, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that Janssen Pharmaceuticals, Inc., (Janssen) has entered into an agreement with Arrowhead Pharmaceuticals, Inc., (Arrowhead) for an exclusive, worldwide license to develop and commercialize ARO-HBV, a Phase 1/2 subcutaneous, ribonucleic acid interference (RNAi) therapy candidate being investigated for the treatment of chronic hepatitis B viral infection.
Celgene Announces Phase 3 STYLE Study of OTEZLA® (apremilast) in Moderate to Severe Scalp Psoriasis Met Primary Endpoint
Mon October 8, 2018 4:37 PM|Business Wire|About: CELG
Libtayo® (cemiplimab-rwlc) Data at ESMO 2018 Congress Provide New Insights in Six Tumor Types Under Investigation
Mon October 8, 2018 6:05 PM|PR Newswire|About: REGN
Genentech to Present New Positive Data from Its Broad Cancer Immunotherapy Program and across a Wide Range of Cancers at the European Society for Medical Oncology (ESMO) 2018 Congress
Tue October 9, 2018 1:00 AM|Business Wire|About: RHHBY
INDIANAPOLIS, Oct. 4, 2018 /PRNewswire/
Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes
Thu October 4, 2018 6:45 AM|Business Wire|About: MRK
Merck’s HIV Therapy DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Antiretroviral Treatment Regimens
Health Canada OKs AbbVie's elagolix for endometriosis-related pain
Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy
Wed October 3, 2018 8:30 AM|Business Wire|About: GILD
– Biktarvy Showed High Efficacy and a Demonstrated Tolerability Profile Through 96 Weeks –
New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy
Sat October 6, 2018 7:30 AM|GlobeNewswire|About: BIIB
Thu September 27, 2018 7:52 PM|PR Newswire|About: LLY
INDIANAPOLIS, Sept. 27, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY)
Lilly's Emgality™ (galcanezumab-gnlm) Receives U.S. FDA Approval for the Preventive Treatment of Migraine in Adults
by Nick Paul Taylor |
Sep 28, 2018 7:33am
Roche has paid €70 million ($81 million) upfront to buy Tusk Therapeutics. The takeover gives Roche control of an anti-CD25 antibody that depleted levels of regulatory T cells (Tregs) in preclinical tests
Thursday, September 20, 2018 - 8:00amEDT
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE)
PFIZER GRANTED FDA BREAKTHROUGH THERAPY DESIGNATION FOR 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE FOR THE PREVENTION OF INVASIVE DISEASE AND PNEUMONIA IN ADULTS AGED 18 YEARS AND OLDER
SAN DIEGO, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
Adamis Pharmaceuticals Receives FDA Approval for Its Lower Dose Symjepi Product
Novartis (NYSE:NVS) unit Sandoz will commercialize.
AstraZeneca's Imfinzi improved survival in late-stage lung cancer study
Sep. 24, 2018 1:29 PM ET|By: Douglas W. House, SA News Editor
Abiomed (ABMD +8.1%) is up average volume on the heels of its announcement of results from a new analysis of real-world data from its Impella Quality Database that showed a relative increase of 24% in average survival in acute myocardial infarction cardiogenic shock patients since Impella's U.S. approval for cardiogenic shock.
Sep. 24, 2018 1:24 PM ET
About: Abbott Laboratories (ABT)
Abbott: MitraClip Success Provides Upside For Stock
September 24, 2018 07:00 AM EDT
FARXIGA Achieved a Positive Result in the Phase III DECLARE-TIMI 58 Trial, a Large Cardiovascular Outcomes Trial in 17,000 Patients with Type 2 Diabetes
AstraZeneca's Imfinzi OK'd in Europe for advanced lung cancer
TOKYO and CHERTSEY, England, Sept. 24, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
Astellas Receives Positive CHMP Opinion for XTANDI® (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer
AstraZeneca's FASENRA shows safety and sustained efficacy in long-term phase III BORA trial in severe eosinophilic asthma
September 18, 2018 06:59 AM EDT
European Medicines Agency Validates Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Multiple Myeloma
Sep. 18, 2018 7:22 AM ET|By: Douglas W. House, SA News Editor
The European Medicines Agency (EMA) accepts for review Bristol-Myers Squibb's (NYSE:BMY) marketing application seeking approval for EMPLICITI (elotuzumab), in combination with Celgene's (NASDAQ:CELG) POMALYST (pomalidomide) and low-dose dexamethasone, for the treatment of adult patients with multiple myeloma (MM)
DUBLIN - September 18, 2018 - Medtronic plc (NYSE:MDT)
(GLOBE NEWSWIRE via COMTEX) --Medtronic Receives FDA Approval for Revised TAVR Labeling and Begins Investigational Study of Low Risk Patients with Bicuspid Valves
AstraZeneca's PT010 shows treatment benefit in late-stage COPD study
Mon September 24, 2018 9:00 PM|PR Newswire|About: AMGN
BLINCYTO® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia
by john carroll — on September 14, 2018 08:37 AM EDT
According to the Albany Times-Union, Regeneron $REGN had already told officials last month that they were expanding their plans for manufacturing, office and lab space in Rensselaer, boosting their initial hiring plans from 1,100 to 1,500 while blueprinting an extra 300,000 square feet of space for the complex.
Zach Hartman Sep. 14, 2018 8:00 AM ET
Merck Tightening Its Grips On Front-Line Lung Cancer
By The ASCO Post
Posted: 9/13/2018 2:20:30 PM
Last Updated: 9/13/2018 5:04:27 PM
(FDA) today approved moxetumomab pasudotox-tdfk (Lumoxiti) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL)
TARRYTOWN, N.Y. and PARIS, Sept. 15, 2018 /PRNewswire/
Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis TARRYTOWN, N.Y. and PARIS, Sept. 15, 2018 /PRNewswire/
Sep. 13, 2018 2:17 PM ET
FDA OKs AstraZeneca's Lumoxiti for type of leukemia
September 12, 2018
Gilead to Develop Hepatitis B Therapies Using Precision's ARCUS Genome Editing Platform
Reuters reports that AstraZeneca (NYSE:AZN) is all in in China, leveraging partnerships with tech giants Alibaba and Tencent, smart cancer diagnostics, all-in-one diabetes kits and artificial intelligence systems to improve ambulance pick-ups to become a broad healthcare provider there.
CARLSBAD, Calif., Sept. 18, 2018 /PRNewswire/ -- Thermo Fisher Scientific, Inc., the world leader in serving science, has licensed CRISPR technologies from the Broad Institute and ERS Genomics (foundational University of California IP) to bolster its genome editing intellectual property (IP) portfolio.
April 09, 2018
Top 10 Sequencing Companies
#1. Illumina Revenues: $2.752 billion in 2017
After years of dominating high-end NGS technologies, Illumina in January announced the launch of a markedly smaller system, the one-cubic-foot iSeq 100 sequencer. At $19,900, the iSeq 100 is a bargain compared to the company’s $50,000 MiniSeq or its NovaSeq, which sells for close to $1 million—with Illumina
RARITAN, NJ, March 15, 2018 –
Janssen Announces U.S. FDA Breakthrough Therapy Designation for Erdafitinib in the Treatment of Metastatic Urothelial Cancer
BEERSE, BELGIUM, September 7, 2018
European Commission expands labelling for Janssen’s INVOKANA® and VOKANAMET® to include positive data on cardiovascular outcomes
September 13, 2018 11:35 AM|Business Wire
FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis (SJIA), a Rare Form of Juvenile Arthritis
September 13, 2018 9:20 AM|PR Newswire
AbbVie Presents Upadacitinib Longer-Term (32-Week) and Patient-Reported Outcomes Data from Phase 2b Atopic Dermatitis Study at 27th European Academy of Dermatology and Venereology (EADV) Congress
eptember 13, 2018 at 7:00 AM EDT
FDA TO REVIEW EYLEA® (AFLIBERCEPT) INJECTION FOR THE TREATMENT OF DIABETIC RETINOPATHY
NORTH CHICAGO, Ill., Sept. 13, 2018 /PRNewswire/ -- AbbVie (NYSE : ABBV )
AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis
Sep. 12, 2018 6:55 AM ET
FDA grants priority review to Merck’s sBLA for KEYTRUDA as monotherapy for treatment of locally advanced or metastatic NSCLC